The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Overall survival associated with real-world treatment sequences in patients with CLL/SLL in the US
In this video, Joanna Rhodes, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, shares findings from a real-world data analysis that explored the overall survival associated with treatment sequences in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the United States. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This was a real-world data analysis using insurance claim data to try and understand what our different treatment sequences are and do they actually have an effect on overall survival. What we found was that for the majority of these different treatment sequences, looking at first-line and second-line treatment, there weren’t significant differences in overall survival unless you’re starting to do anti-CD20 monoclonal antibodies as a monotherapy or if we’re actually bringing chemoimmunotherapy into the backbone...
This was a real-world data analysis using insurance claim data to try and understand what our different treatment sequences are and do they actually have an effect on overall survival. What we found was that for the majority of these different treatment sequences, looking at first-line and second-line treatment, there weren’t significant differences in overall survival unless you’re starting to do anti-CD20 monoclonal antibodies as a monotherapy or if we’re actually bringing chemoimmunotherapy into the backbone. I think that that’s important as in the United States, we’re trying to move away from chemoimmunotherapy, particularly bendamustine and rituximab for initial treatment for CLL and really focus on the types of treatments that we talked about before utilizing our continuous BTK inhibitors, fixed duration therapies with BCL2 inhibitors with either a monoclonal antibody or a BTK inhibitor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Abbvie, AstraZeneca, ADC Therapeutics, Beigene, BMS, Epizyme, Genentech, GenMab, Incyte, Loxo Oncology, Janssen, Johnson and Johnson, Morphosys, Pharmacyclics, Pfizer
Membership on a Board or Advisory Committee: Abbvie, Beigene, Janssen
Research Funding: Acerta, Abbvie, Beigene, Epizyme, Janssen, Loxo Oncology, Oncternal, Pharmacyclics, Velosbios, Merck
